Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New heart pacing strategy could cut defibrillator need

NCT ID NCT05572957

Disease control Sponsor: The First Affiliated Hospital with Nanjing Medical University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether a special heart pacing technique (left bundle branch pacing) combined with standard heart failure drugs can improve heart function better than drugs alone. It includes 50 adults with non-ischemic heart failure and a specific heart block. The main goal is to see if this combination reduces the number of patients who need a defibrillator implant.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
left bundle branch pacing (a heart pacing procedure) combined with guideline-directed medical therapy (a set of heart failure drugs)
What this could lead to
If it works, this approach could reduce the need for implantable defibrillators in heart failure patients, offering a less invasive option.
What could go wrong
This is a small, early-phase study with only 50 participants, so results may not apply to everyone. The pacing procedure also carries risks like infection or lead displacement.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 50 people

The number the study aims to enrol. It can still change while the study runs.

Started

Oct 2022

Expected to finish

Oct 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 80 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Non-ischemic cardiomyopathy with LVEF≤35% as assessed by echocardiography, NYHA class II-III, and less than 3 months of optimized (complete) GDMT\*; 2. Sinus rhythm (paroxysmal atrial fibrillation may be present) with complete left bundle branch block meeting STRAUSS's criteria; 3. Between the ages of 18 and 80; 4. With informed consent signed. Exclusion Criteria: 1. After mechanical tricuspid valve replacement; 2. Ischemic cardiomyopathy; 3. Persistent AF without AV node ablation; 4. History of unexplained syncope or indications for pacemaker implantation; 5. Indications for ICD implantation such as a history of sustained ventricular tachycardia or sudden cardiac arrest; 6. Unstable angina, acute MI, CABG or PCI within the past 3 months; 7. Enrollment in any other study； 8. A life expectancy of less than 12 months; 9. Pregnant or with child-bearing potential; 10. History of heart transplantation.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Heart failure are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

heart failure intrinsic cardiomyopathy progressive familial heart block, type 1A systolic heart failure

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Heart failure Left bundle branch block Non-ischemic cardiomyopathy

Contacts and locations

Locations

  • Fujian Medical University Union Hospital

    Fuzhou, Fujian, China

  • Fuwai Hospital, Chinese Academy of Medical Sciences

    Beijing, Beijing Municipality, China

  • The First Affiliated Hospital of Dalian Medical University

    Dalian, Liaoning, China

  • The First Affiliated Hospital of Wenzhou Medical University

    Wenzhou, Zhejiang, China

  • The First Affiliated Hospital with Nanjing Medical University

    Nanjing, Jiangsu, 210029, China

  • West China Hospital, Sichuan University

    Chengdu, Sichuan, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.